GW Pharmaceuticals Gets Canadian Approval for Cannabis Drug
April 19 (Bloomberg) -- GW Pharmaceuticals Plc, a U.K. company developing cannabis-based drugs, said it won Canadian approval to market its Sativex spray for pain related to multiple sclerosis. Shares jumped as much as 14 percent.
Health Canada is the first regulatory agency to approve Sativex, Salisbury, England-based GW Pharmaceuticals said in a Regulatory News Service statement. GW and its marketing partner, Bayer AG, expect to introduce the product in Canada in late spring, the company said.
Sativex is derived from two principle compounds found in the cannabis plant, cannabidiol and Delta-9 Tetrahydrocannabinol, or THC, a psychoactive ingredient.
GW Pharmaceuticals shares rose 13 pence, or 11 percent, to 134 pence as of 12:12 p.m. in London, after rising as high as 138.5 pence.
Health Canada is the first regulatory agency to approve Sativex, Salisbury, England-based GW Pharmaceuticals said in a Regulatory News Service statement. GW and its marketing partner, Bayer AG, expect to introduce the product in Canada in late spring, the company said.
Sativex is derived from two principle compounds found in the cannabis plant, cannabidiol and Delta-9 Tetrahydrocannabinol, or THC, a psychoactive ingredient.
GW Pharmaceuticals shares rose 13 pence, or 11 percent, to 134 pence as of 12:12 p.m. in London, after rising as high as 138.5 pence.
posted by Terry at
5:41 AM
0 Comments:
Post a Comment
<< Home